Type 2 Diabetes Mellitus
Conditions
Brief summary
The purpose of this study is to obtain information on efficacy and safety of SHR3824 with metformin over 24 weeks and 52 weeks in metformin monotherapy poorly glycemic controlled chinese Type 2 Diabetes. Efficacy and safety will be evaluated by comparing the effect of SHR3824 with metformin to placebo with metformin when given in oral doses.
Detailed description
A phase III clinical study on efficacy and safety of SHR3824 combined with metformin for type 2 diabetes with poor glucose control in metformin monotherapy (multicenter, randomized, double-blind, placebo-parallel control). The 450 subjects received at least eight weeks of metformin monotherapy at a steady dose of 1500 mg or more before screening. Evaluation of efficacy: compared with the group of placebo combined with metformin, HbA1c, fasting plasma glucose, postprandial plasma glucose, fasting body weight and blood pressure changes in the SHR3824 with metformin group
Interventions
DRUGPlacebo
Once daily, 24 weeks
DRUGSHR3824
Once daily, 52 weeks
DRUGmetformin
Three times daily, 52 weeks
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients must have a diagnosis of type 2 diabetes mellitus; * Patients with type 2 diabetes mellitus treated with metformin monotherapy for ≥ 8 weeks and poor glycemic control, metformin dose stabilized ≥1500mg / day; * FPG\<=15mmol/L; * Hemoglobin A1c levels \>=7.0% and \<=10.5%; * Body mass index (BMI) 19 to 35 kg/m2;
Exclusion criteria
* Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (acromegaly, Cushing's syndrome, etc.); * Past or current history of severe diabetic complications (proliferative diabetic retinopathy, stage III or later stage overt nephropathy, diabetic ketoacidosis, or serious diabetic neuropathy); * Systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg on the start or end day of the run-in period; * History of myocardial infarction, unstable angina, or cerebrovascular disorder within 6 months before the start of the run-in period; * Past or current history of malignant tumor; * Past or current history of drug hypersensitivity such as shock and anaphylactoid symptoms; * Pregnant women, lactating mothers, or women of childbearing potential; * Any condition that subjects are assessed to be ineligible by the investigator (sub investigator).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adjusted Mean Change in HbA1c Levels | Baseline to Week 24 | Compared with the placebo with metformin group, mean change in HbA1c Levels in SHR3824 with metformin group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adjusted Mean Change in Fasting Plasma Glucose | Baseline to Week 24 | Compared with the placebo with metformin group, mean change in Fasting Plasma Glucose Levels in SHR3824 with metformin group |
| The number of volunteers with adverse events as a measurement of safety | Baseline to Week 52 | Compared with the placebo with metformin group, the incidence of adverse events in SHR3824 with metformin group |
Countries
China
Contacts
Primary ContactWENG Jianping, professor
Backup ContactCHEN Jianwen, professor
Outcome results
None listed